Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V205C (rHA) vs V205C (HSA) in Children
NCT00109278Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2004
- Primary completion
- May 2005
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 2, randomised, double-blind trial of M-M-R II in measles, mumps and rubella (2 arms), sponsored by Merck & Co. Primary endpoint: Antibody response rate to measles at 6 weeks. Started Oct 2004; status: completed.
02
Drugs
M-M-R II
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on NCT00109278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109278.